Harmony Biosciences Announces Exclusive Agreement to Develop and Commercialize Tpm-1116, a Highly Potent and Selective Oral Orexin-2 Receptor Agonist
Harmony Biosciences宣佈簽訂獨家協議,開發和商業化Tpm-1116,一種高效的選擇性口服Orexin-2受體激動劑
Harmony Biosciences Announces Exclusive Agreement to Develop and Commercialize Tpm-1116, a Highly Potent and Selective Oral Orexin-2 Receptor Agonist
Harmony Biosciences宣佈簽訂獨家協議,開發和商業化Tpm-1116,一種高效的選擇性口服Orexin-2受體激動劑
使用瀏覽器的分享功能,分享給你的好友吧